Table 1.

Important Characteristics of the Included Studies.

Study	n	Design	Follow-up (months)	HE4 detection	Age (years)	% Endo-metroid	FIGO (%)				Grade (%)			Lymph node (%)
							I	II	III	IV	I	II	III	+ive	-ive
Abbink 201819	157	RET	60	CLEIA	63 ± 4.3	78	63	7	17	13	17	45	38	25	75
Bignotti 201120	138	RET	33 ± 21	ELISA		79	77		23		18	82		18	82
Brennan 201421	373	PROSP	37 ± 18	CLMEIA	61.2 ± 10	85	75	8	6	1	49	31	20	10	90
Brennan 201522	98	RET	60	CLMEIA	65 ± 22	70	59	7	26	8	17	39	42	23	77
Deng 201523	72	PROSP		IHC	58.9 ± 12	47	63	8	25	4				28	72
Li 201524	102	RET	9-116	IHC	58.1 ± 14	48	60	7	27	6	59.8	6.86	22	28	52
Mutz-dehbalaie 201225	183	RET	36 ± 35	CLMEIA	68 ± 15	72	56	9	27	7	20	38	42	25	75
Stiekema 201726	88	RET	48 ± 40	ECLIA	65 ± 13	64	68	32		0	48		52	37	63
Zanotti 201227	193	RET	31 ± 25	CLMEIA	66 ± 19	79	55	18	16	5	18	46	36	16	84

Abbreviations: CLEIA, chemiluminescent enzyme immunoassay; CLMEIA, chemiluminescent microparticle immunoassays; ECLIA, electrochemiluminescensce immunoassay; ELISA, enzyme-linked immunosorbent assay; IHC, immunohistochemistry; PROSP, prospective; RET, retrospective.